CN1185947A - 治疗尖锐湿疣的组合物 - Google Patents
治疗尖锐湿疣的组合物 Download PDFInfo
- Publication number
- CN1185947A CN1185947A CN97122670A CN97122670A CN1185947A CN 1185947 A CN1185947 A CN 1185947A CN 97122670 A CN97122670 A CN 97122670A CN 97122670 A CN97122670 A CN 97122670A CN 1185947 A CN1185947 A CN 1185947A
- Authority
- CN
- China
- Prior art keywords
- compositions
- condyloma acuminatum
- ointment
- tea catechin
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010059313 Anogenital warts Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims description 18
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 239000002674 ointment Substances 0.000 claims description 11
- 239000000829 suppository Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 7
- 241000701806 Human papillomavirus Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 6
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 claims description 6
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 claims description 6
- 238000011284 combination treatment Methods 0.000 claims 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract description 9
- 235000005487 catechin Nutrition 0.000 abstract description 9
- 229950001002 cianidanol Drugs 0.000 abstract description 8
- 210000004392 genitalia Anatomy 0.000 description 10
- 210000001215 vagina Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000003679 cervix uteri Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 5
- 208000000260 Warts Diseases 0.000 description 4
- 201000010153 skin papilloma Diseases 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 3
- 229930184207 Polyphenon Natural products 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229930013783 (-)-epicatechin Natural products 0.000 description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 description 2
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000021145 human papilloma virus infection Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- 229930013884 (+)-gallocatechin Natural products 0.000 description 1
- 235000007243 (+)-gallocatechin Nutrition 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010062317 Condyloma latum Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
用于治疗HPV感染的尖锐湿疣的组合物,所述组合物含有作为主要组分的茶儿茶素。该药物没有副作用,而且可以易于患者本人施用或插入到感染部位。
Description
本发明涉及治疗尖锐湿疣的组合物，或更具体地说，涉及治疗因人乳头瘤病毒引起的尖锐湿疣，并以儿茶素为主要组分的组合物。
尖锐湿疣是在皮肤或男女生殖器粘膜上可检测的一种疣，是由人乳头瘤病毒(HPV)引起的。在男性中，感染部位主要在龟头区、冠状沟、包皮、肛门区、尿道口；而在女性是阴道、阴唇、肛门区、尿道口。临床症状出现于感染后1-6个月，平均为3个月，但患者通常不会注意这些症状。这种疣表现为与众不同的乳头状或鸡冠样肿瘤，而且有积累和多发的倾向，通常为红色或棕红色。检测尖锐湿疣的方法是取组织或从感染部位涂片然后确定所述病毒的DNA。根据该方法，检测率几乎为100％。这种病毒的HPV6和11型是最常检测到的种类，由于从阴茎癌、子宫颈癌和尖锐温疣的恶性鳞状细胞癌中检测到了HPV16，所以很可能HPV16是与恶性尖锐湿疣有关的。
目前已尝试过的治疗因人乳头瘤病毒引起的尖锐湿疣的方法是物理方法如外科手术切除、电烙、冷冻外科手术、激光治疗等，和药物治疗如施用目前可得到的普达非伦脂、5-氟尿嘧啶、争光霉素、干扰素等。但考虑到感染部位，外科手术会给患者带来苦恼，而局部给药会有副作用。因此目前还没有令人信服的治疗方法。
尖锐湿疣的发生率高，而且除非坚持治疗，否则很难全愈。因此，非常需要一种高度安全并方便的治疗方法。
因此，所需的治疗人乳头瘤病毒所引起的尖锐湿疣的方法应是一种对患者来说简便易行的治疗方法，如可以由患者本人应用到感染部位的药物，而且所述药物应在相对短的使用时间内有良好的效果并没有副作用。
本发明人努力寻找没有副作用的天然物质，所述物质由患者本人长期应用是安全的，而且效果明显；在进行了长期的试验后，我们发现儿茶素，即日常饮料茶中的一种组分是有效的，因此产生了本发明。
因此，本发明涉及用于治疗人乳头瘤病毒所引起的尖锐湿疣的组合物，该组合物以儿茶素为主要组分。
在下列通式1中列出了本发明的茶儿茶素：其中R1代表H或OH，R2代表H或
茶儿茶素更具体地说是表儿茶素、表儿茶素棓酸盐、表棓儿茶素棓酸盐、棓儿茶酸等(包括其衍生物)。这些儿茶素可单独使用或两种或多种组合混合在一起。其中特别需要以(-)-表棓儿茶素棓酸盐为主要组分。例如：Polyphenon 100TM(由Mitsui Norin Co.生产的；组成：(+)-棓儿茶酸1.44％，(-)-表儿茶素5.81％，(-)-表棓儿茶素17.57％，(-)-表儿茶素棓酸盐12.51％，(-)-表棓儿茶素棓酸盐53.90％)或PolyphenonETM(由MitsuiNorin Co.生产的；组成：(-)-表儿茶素10.8％，(-)-表棓儿茶素9.2％，(-)-表儿茶素棓酸盐6.5％，(-)-表棓儿茶素棓酸盐54.8％，(-)-棓儿茶酸4.0％)。
可将本发明治疗尖锐湿疣的方法例如以软膏如霜、胶状胨、乳液的形式使用；或以栓剂如胶囊的形式使用，而且通常将茶儿茶素组分与赋形剂、填充剂、乳化剂、分散剂等混合。凡士林适宜作为软膏基。对于软膏来说，茶儿茶素的含量应在5-20％(重量)，优选12-18％(重量)之间，最佳为15％(重量)。在栓剂的情况下，儿茶素的含量应为100-500mg/胶囊，优选200-300mg/胶囊，或最佳为250mg/胶囊。
软膏的典型使用实例是将含5-20％重量儿茶素的凡士林霜直接应用到外生殖器或阴道的感染部位，每天施用一次到数次，连续1-2个月。栓剂的典型使用实例是，若感染部位是子宫颈或阴道，则将含100-500mg茶儿茶素的胶囊插入，每天一次到数次，连续1-2个月。
由于主要组分是来自经常消费的茶的天然物质，所以用以茶儿茶素为主要组分的本发明组合物来治疗尖锐湿疣没有副作用，而且可以长期施用。此外，患者本人很容易施用所述药物或将其插入到感染部位。本发明用于治疗尖锐湿疣的组合物有很高的潜在实践用途。
本发明的另一方面是将人乳头瘤病毒感染的尖锐湿疣治疗有效量的茶儿茶素应用到患者感染部位以治疗人乳头瘤病毒感染的尖锐湿疣的方法。
参考下列实施例将更详细地说明本发明，所述实施例对本发明范围不构成限制。试验实施例1
将主要以茶儿茶素(商品名Polyphenon 100由Mitsui Norin Co.生产；其主要组分：(-)-表棓儿茶素棓酸盐)为主要组分的凡士林基阴道润滑剂组成的软膏应用到健康小鼠(每组50只)的子宫颈，儿茶素的剂量为8mg、15mg、或38mg，连续7天。此后，进行病理学和组织学检验，测定到除在38mg剂量组的小鼠中有中等程度的炎症反应外，没有观察到副作用。实施例1
在中国医学科学研究院癌症研究所(北京)，用15名诊断为患HPV感染的尖锐湿疣的妇女进行本发明的临床试验。根据临床检验、细胞学、阴道镜和病理学试验确定所有患者在外阴(外生殖器)、阴道和/或子宫颈患有湿疣。15名患者中有2名有两个感染部位。疣的直径为0.2-2cm。
用含10-15％凡士林基的阴道润滑剂和5-20％的茶儿茶素(商品名：Polyphenon 100，由Mitsui Norin Co.生产的，粗儿茶素含量为约90％，其主要组分为(-)-表棓儿茶素棓酸盐)的软膏或用含100-500mg/胶囊上述茶儿茶素的栓剂对这15名患者进行试验。将所述软膏应用到外生殖器，将栓剂应用到阴道和子宫颈，本发明的治疗每天一次，连续约2个月。
在治疗期间，进行感染部位的检验和阴道镜检验。所得的结果列于表1。如表中所示，当感染部位完全消失时，认为是治愈了，当50％或50％以上消失时，认为得到改善，而当不到50％或没有消失时，认为没有作用。表1感染部位 患者数 治愈 改善 无效外生殖器 9 4 3 2阴道 6 0 1 5子宫 2 1 0 1总计(％) 17 5 4 8
(29.4％) (23.5％) (47.1)
从表中可以看出，9个外生殖器尖锐湿疣中的7个病例(77.8％)有明显的作用(被治愈或得到改善)。子宫颈感染的情况下，肿瘤完全消失，因此可以说被治愈。在该过程中，除了有些患者在感染部位有轻微的疼痛或炎症，而少数感觉有些痒外，没有观察到明显的副作用。实施例2
与实施例1一样，在中国医学科学研究院癌症研究所(北京)，用一组33名诊断患HPV感染的尖锐湿疣的妇女进行临床试验。在该组中，8名患者有两个感染部位。结果列于表2。从表中可以看出，92％的外生殖器尖锐湿疣和70％的阴道尖锐湿疣得到治愈或改善，在子宫颈尖锐湿疣的情况下，所有病例均被治愈。41个中的25个病例得到治愈，治愈率为61％。表2感染部位 患者数 治愈 改善 无效外生殖器 26 18 6 2阴道 10 2 5 3子宫颈 5 5 0 0总计(％) 41 25 11 5
(61.0) (26.8) (12.2)实施例3
与实施例1一样，在中国医学科学研究院癌症研究所(北京)，用一组22名诊断患HPV感染的尖锐湿疣的妇女进行临床试验。结果列于表3。从表中可以看出，16例外生殖器尖锐湿疣中，7例被治愈，6例得到改善；在阴道尖锐湿疣的情况下，6个病例中的3例被治愈，2例得到改善，总有效率为83.3％。表3感染部位 患者数 治愈 改善 无效外生殖器 16 7 6 3阴道 6 3 2 1总计(％) 22 10 8 4
(45.5) (36.4) (18.2)
于1996年11月申请的日本专利申请8-321195的全文公开，包括说明书、权利要求和摘要全文引入本文作为参考。
Claims (8)
1 用于治疗HPV-感染的尖锐湿疣的组合物，所述组合物含有作为主要组分的茶儿茶素。
2 根据权利要求1的组合物，其中所述茶儿茶素含有作为主要组分的(-)-表棓儿茶素棓酸盐。
3 根据权利要求1的组合物，其中所述组合物是软膏形式，所述软膏含5-20％重量的茶儿茶素。
4 根据权利要求1的组合物，其中所述组合物是栓剂形式，所述栓剂含100-500mg/胶囊。
5 治愈人乳头瘤病毒所引起的尖锐湿疣的方法，所述方法包括用以茶儿茶素为主要组分的组合物治疗感染部位。
6 根据权利要求5的方法，其中所述组合物是软膏或栓剂形式。
7 根据权利要求5的方法，其中所述组合物是是软膏形式，所述软膏含5-20％重量的茶儿茶素。
8 根据权利要求5的组合物，其中所述组合物是栓剂形式，所述栓剂含100-500mg/胶囊。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP321195/96 | 1996-11-18 | ||
| JP32119596A JP3213557B2 (ja) | 1996-11-18 | 1996-11-18 | 茶カテキンを有効成分として含有する尖圭コンジローマ治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1185947A true CN1185947A (zh) | 1998-07-01 |
| CN1086290C CN1086290C (zh) | 2002-06-19 |
Family
ID=18129859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97122670A Expired - Lifetime CN1086290C (zh) | 1996-11-18 | 1997-11-17 | 治疗尖锐湿疣的组合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5795911A (zh) |
| EP (1) | EP0842660B1 (zh) |
| JP (1) | JP3213557B2 (zh) |
| KR (1) | KR100312252B1 (zh) |
| CN (1) | CN1086290C (zh) |
| AT (1) | ATE288266T1 (zh) |
| AU (1) | AU716120B2 (zh) |
| CA (1) | CA2221370C (zh) |
| DE (2) | DE69732402T2 (zh) |
| ES (1) | ES2232849T3 (zh) |
| FR (1) | FR12C0077I2 (zh) |
| PT (1) | PT842660E (zh) |
| TW (1) | TW371628B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727275A (zh) * | 2016-12-15 | 2017-05-31 | 珠海聚焦先导生物研究院有限公司 | 一种治疗阴道炎的栓剂组合物 |
| CN107349197A (zh) * | 2017-07-13 | 2017-11-17 | 黄冈师范学院 | 一种儿茶素在制备治疗皮肤乳头状瘤的药物上的应用 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968973A (en) * | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
| US6197808B1 (en) * | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
| JP2003525839A (ja) | 1997-09-29 | 2003-09-02 | ベイジン・ファイ・チャイニーズ・ファーマスーティカル・ファクトリー | 金蕎麦群成物、その製造方法および分析方法並びにその使用 |
| CN1063957C (zh) | 1997-09-29 | 2001-04-04 | 北京华颐中药制药厂 | 一种金荞麦制剂的制备方法 |
| EP0938897A1 (en) * | 1997-12-26 | 1999-09-01 | Japanese Foundation For Cancer Research | Telomerase inhibitor |
| US6030622A (en) * | 1998-06-23 | 2000-02-29 | Shehadeh; Ahmad Abdallah | Herbal extract composition and method with immune-boosting capability |
| US6492389B1 (en) * | 1998-07-21 | 2002-12-10 | Thomas Jefferson University | Small molecule inhibitors of BCL-2 proteins |
| KR100319973B1 (ko) * | 1998-12-05 | 2002-04-22 | 이인수 | 녹차카테킨을 유효성분으로 하는 자궁경부 상피내종양 예방 또는 치료제 조성물 |
| ATE466577T1 (de) | 2001-05-03 | 2010-05-15 | Cornell Res Foundation Inc | Behandlung von krankheiten, die durch hpv verursacht werden |
| DE122009000073I1 (de) | 2001-11-19 | 2010-03-25 | Medigene Ag Lochhamer Strase 1 | Arzneimittel zur behandlung von viralen haut- und tumorerkrankungen |
| DE10156794B4 (de) * | 2001-11-19 | 2006-05-18 | Medigene Ag | Arzneimittel zur Behandlung von Warzen |
| US7108868B2 (en) * | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
| US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
| US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| JP4723239B2 (ja) * | 2002-04-30 | 2011-07-13 | ユニジェン・インコーポレーテッド | 治療剤としての遊離−ｂ−環フラボノイド類とフラバン類との混合物の製剤 |
| US7780992B2 (en) | 2002-12-08 | 2010-08-24 | Tareq Abduljalil Albahri | Antiviral medicament |
| WO2004089392A1 (en) | 2003-04-04 | 2004-10-21 | Unigen Pharmaceuticals, Inc. | Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
| US7763588B2 (en) * | 2003-06-13 | 2010-07-27 | The Salk Institute For Biological Studies | Method for increasing cognitive function and neurogenesis |
| BRPI0414063A (pt) * | 2003-09-02 | 2006-10-24 | Unigen Pharmaceuticals Inc | formulação de uma mistura de flavonóides de anel b livre e flavanos para uso na prevenção e tratamento de declìnio cognitivo e danos de memória relacionados à idade |
| US20050079235A1 (en) * | 2003-10-09 | 2005-04-14 | Eggert Stockfleth | Use of a polyphenol for the treatment of actinic keratosis |
| AR045865A1 (es) * | 2003-10-09 | 2005-11-16 | Medigene Ag | El uso de un polifenol para el tratamiento de una lesion cancerosa o pre-cancerosa de la piel |
| CN100337690C (zh) * | 2005-02-07 | 2007-09-19 | 上海复旦张江生物医药股份有限公司 | 一种评价治疗尖锐湿疣药物有效性的方法 |
| US20070082073A1 (en) * | 2005-05-18 | 2007-04-12 | University Of South Florida | Catechin Adjuvants |
| US8044098B2 (en) * | 2005-08-02 | 2011-10-25 | Shenghua Guangzhou Pharmaceutical Science & Technology Co., Ltd. | Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection |
| KR100801891B1 (ko) | 2006-11-02 | 2008-02-12 | 한상진 | 천연물질을 이용한 생식기 염증 예방 또는 치료용 약제학적 조성물 |
| EP2179722A1 (en) | 2008-10-24 | 2010-04-28 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Topical formation for preventing sexual transmission of viral infection |
| ES2349966B1 (es) * | 2008-10-30 | 2011-11-18 | Ignacio Umbert Millet | Formulaciones topicas para el tratamiento de verrugas. |
| US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
| WO2012100835A1 (en) | 2011-01-28 | 2012-08-02 | Laboratorios Del Dr. Esteve, S.A. | Methods and compositions for the treatment of aids |
| WO2014110284A1 (en) | 2013-01-09 | 2014-07-17 | Bacterin International, Inc. | Bone graft substitute containing a temporary contrast agent and a method of generating such and a method of use thereof |
| IL254568B2 (en) | 2015-03-19 | 2023-11-01 | Wendy Anne Epstein | Catechin compounds extracted from tea leaves for the treatment of female sexual disorders |
| MX367243B (es) * | 2016-02-04 | 2019-08-09 | Maria Del Carmen Ramirez Olvera | COMPOSICIÓN DE EXTRACTOS DE PLANTAS QUE INCREMENTAN LOS BACILOS DE DöDERLEIN, USADA PARA EL TRATAMIENTO DE ENFERMEDADES DE TRANSMISIÓN SEXUAL (ETS) Y DEL VIRUS DEL PAPILOMA HUMANO (VPH), CON EFECTO AFRODISIACO. |
| WO2024003061A1 (en) | 2022-06-30 | 2024-01-04 | Lo.Li. Pharma S.R.L. | Composition for the treatment of the human papillomavirus infection (hpv) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2128207B1 (zh) * | 1971-03-11 | 1974-08-02 | Zyma Sa | |
| US5159069A (en) * | 1988-12-20 | 1992-10-27 | Yamanouchi Pharmaceutical Co., Ltd. | Sulfated tannins and their salts |
| JP2727471B2 (ja) * | 1989-09-14 | 1998-03-11 | 三井農林株式会社 | インフルエンザウィルス感染予防剤 |
| JPH03141220A (ja) * | 1989-10-26 | 1991-06-17 | Tsumura & Co | 抗レトロウイルス剤 |
| JP3019996B2 (ja) * | 1990-03-01 | 2000-03-15 | 三井農林株式会社 | 白癬治療剤 |
| US5211944A (en) * | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
| DE4211238C2 (de) * | 1992-04-03 | 1994-10-27 | Edward I Budowskij | Verwendung von 2',5'-Oligoadenylaten zur Behandlung von Papillomatosen |
| US5605929A (en) * | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| US5648377A (en) * | 1993-12-21 | 1997-07-15 | Indena S.P.A. | Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals |
| GB2293548A (en) * | 1994-09-29 | 1996-04-03 | Joan Louise Hibberd | Treatment of herpes infections |
| IT1275905B1 (it) * | 1995-03-14 | 1997-10-24 | Indena Spa | Frazioni polifenoliche di te', loro uso e formulazioni che le contengono |
| US5576013A (en) * | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
| JPH1036260A (ja) * | 1996-07-18 | 1998-02-10 | Mitsui Norin Kk | 抗ガン剤の効力増強方法 |
-
1996
- 1996-11-18 JP JP32119596A patent/JP3213557B2/ja not_active Expired - Lifetime
-
1997
- 1997-04-10 US US08/835,920 patent/US5795911A/en not_active Expired - Lifetime
- 1997-10-21 TW TW086115494A patent/TW371628B/zh not_active IP Right Cessation
- 1997-11-10 AU AU44438/97A patent/AU716120B2/en not_active Expired
- 1997-11-17 CA CA002221370A patent/CA2221370C/en not_active Expired - Lifetime
- 1997-11-17 CN CN97122670A patent/CN1086290C/zh not_active Expired - Lifetime
- 1997-11-18 KR KR1019970060940A patent/KR100312252B1/ko not_active IP Right Cessation
- 1997-11-18 AT AT97120182T patent/ATE288266T1/de active
- 1997-11-18 PT PT97120182T patent/PT842660E/pt unknown
- 1997-11-18 ES ES97120182T patent/ES2232849T3/es not_active Expired - Lifetime
- 1997-11-18 DE DE69732402T patent/DE69732402T2/de not_active Expired - Lifetime
- 1997-11-18 DE DE200912000072 patent/DE122009000072I2/de active Active
- 1997-11-18 EP EP97120182A patent/EP0842660B1/en not_active Expired - Lifetime
-
2012
- 2012-12-20 FR FR12C0077C patent/FR12C0077I2/fr active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727275A (zh) * | 2016-12-15 | 2017-05-31 | 珠海聚焦先导生物研究院有限公司 | 一种治疗阴道炎的栓剂组合物 |
| CN107349197A (zh) * | 2017-07-13 | 2017-11-17 | 黄冈师范学院 | 一种儿茶素在制备治疗皮肤乳头状瘤的药物上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0842660A1 (en) | 1998-05-20 |
| FR12C0077I2 (fr) | 2013-08-16 |
| DE69732402T2 (de) | 2006-01-19 |
| US5795911A (en) | 1998-08-18 |
| EP0842660B1 (en) | 2005-02-02 |
| KR100312252B1 (ko) | 2002-02-19 |
| AU4443897A (en) | 1998-06-04 |
| CN1086290C (zh) | 2002-06-19 |
| DE122009000072I2 (de) | 2011-07-21 |
| CA2221370C (en) | 2004-03-02 |
| FR12C0077I1 (zh) | 2013-02-01 |
| KR19980042555A (ko) | 1998-08-17 |
| AU716120B2 (en) | 2000-02-17 |
| ES2232849T3 (es) | 2005-06-01 |
| TW371628B (en) | 1999-10-11 |
| PT842660E (pt) | 2005-05-31 |
| DE69732402D1 (de) | 2005-03-10 |
| JP3213557B2 (ja) | 2001-10-02 |
| ATE288266T1 (de) | 2005-02-15 |
| DE122009000072I1 (de) | 2010-03-25 |
| JPH10147525A (ja) | 1998-06-02 |
| CA2221370A1 (en) | 1998-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1086290C (zh) | 治疗尖锐湿疣的组合物 | |
| Bachmann et al. | Diagnosis and treatment of atrophic vaginitis | |
| Willhite et al. | Urogenital atrophy: prevention and treatment | |
| Kirtschig | Lichen sclerosus—presentation, diagnosis and management | |
| Manonai et al. | The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study | |
| Crandall | Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy | |
| US5968973A (en) | Method for treating hyperplasia | |
| Drake et al. | Guidelines of care for warts: human papillomavirus | |
| MX2008009177A (es) | Metodo para tratar vaginitis atrofica. | |
| Syed et al. | Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males: a placebo-controlled, double-blind, comparative study | |
| US6197808B1 (en) | Methods for treating hyperplasia | |
| Lê et al. | Characteristics of reproductive life and risk of breast cancer in a case-control study of young nulliparous women | |
| WO2000033832A1 (en) | Chemical composition for treating cervical intraepithelial neoplasia i, ii, iii, iv and cervicitis | |
| CN101049329A (zh) | 当归油在升高内源性雌二醇水平,用于治疗雌二醇相关性疾病的用途 | |
| CN108619136B (zh) | 一种抗hpv的制剂 | |
| CN115837054B (zh) | 一种防治hpv感染和阴道炎的中药组合物、制备方法和应用 | |
| WO2020128939A1 (en) | Composition for the treatment of female sexual dysfunctions | |
| Mark | Medroxyprogesterone acetate as a contraceptive for female drug addicts | |
| Castelo-Branco et al. | Compounds for the treatment of atropic vaginitis | |
| CN108853007B (zh) | 一种治疗功能性子宫出血的凝胶制剂及其用途 | |
| Kavitha | Vulvar Disorders | |
| CN102049009B (zh) | 含有莪术油和冰片的药物组合物的用途 | |
| CN116421705A (zh) | 降低宫颈癌发病风险的药物制剂 | |
| CN100418559C (zh) | 一种治疗产后及流产并发症的中药组合物及其制备方法 | |
| von Krogh | Current treatment of genital warts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NITTO FOOD CO., LTD. Free format text: FORMER NAME OR ADDRESS: MITSUI NORIN KK Owner name: MITSUI NORIN KK Free format text: FORMER NAME OR ADDRESS: NITTO FOOD CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Nitto Food Co.,Ltd. Patentee before: Mitsui Norin Co.,Ltd. Patentee after: Mitsui Norin Co.,Ltd. Patentee before: Nitto Food Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20020619 |